Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.

177Lu meningiomas oncology peptide receptor radionuclide therapy

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 27 11 2023
accepted: 25 06 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: aheadofprint

Résumé

Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with

Identifiants

DOI: 10.2967/jnumed.123.266956 PMID: 39142827
pubmed: 39142827
pii: jnumed.123.266956
doi: 10.2967/jnumed.123.266956
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Stefano Severi (S)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Ilaria Grassi (I)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Alberto Bongiovanni (A)

Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy; dr.bongiovanni@gmail.com.

Silvia Nicolini (S)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Irene Marini (I)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Donatella Arpa (D)

Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Emilia Romagna, Italy.

Nicoletta Ranallo (N)

Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Irene Azzali (I)

Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Valentina Di Iorio (V)

Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Emilia Romagna, Italy.

Anna Sarnelli (A)

Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Monti Manuela (M)

Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Elena Amadori (E)

Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Lucia Fabbri (L)

Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Emilia Romagna, Italy.

Daniela Bartolini (D)

Pathology Unit, "Maurizio Bufalini" Hospital, Cesena, Italy.

Luigino Tosatto (L)

Department of Neurosciences, Neurosurgery Division "M Bufalini" Hospital, Cesena, Emilia Romagna, Italy.

Francesco Di Meco (F)

Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland.

Lorena Gurrieri (L)

Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Nada Riva (N)

Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Luana Calabro (L)

Department of Oncology, University Hospital of Ferrara, Cona, Italy; and.
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

Federica Matteucci (F)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Giovanni Paganelli (G)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Maddalena Sansovini (M)

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Classifications MeSH